Bionomics Results Presentation Deck
BNC210: A Best-In-Class Development Candidate
With a Profile Compatible as an Acute Non-Sedating Anxiolytic
ā
4
ā
Novel negative allosteric modulator of a7 nAChR for treatment of anxiety and stressor-related disorders
Extensive safety database from 13 clinical trials completed to date with exposure in over 500 subjects
supporting a non-sedating, non-addicting anxiolytic profile
Has achieved clinical Proof of Target Engagement (PTE), Proof of Mechanism (PoM) in panic model
setting and Proof of Concept (PoC) in Generalized Anxiety Disorder (GAD)
In development for underserved markets with >22 million patients in the US alone suffering from SAD
and PTSD and no new FDA approved therapies in nearly two decades; peak annual sales for acute SAD
of $1.7B and for chronic PTSD of $2.6B
Strong proprietary protection with patent coverage through late 2030's
BionomicsView entire presentation